Health Care • Biotechnology: Pharmaceutical Preparations
$0.60 ▼ -0.17
(-21.95%)
MKT CAP: $79.8M • VOL: 80.50M
52W L $1 52W H $3
ROARABLE / RQD
E • 34/100
PIOTROSKI
2 / 9
INO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $65.3K | $217.8K | $832.0K |
| YoY Revenue Growth % | -70.0% | -73.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$86.8M | -$112.4M | -$143.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$85.0M | -$107.0M | -$135.0M |
| EBITDA (Normalized) | -$86.6M | -$112.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$88.6M | -$104.1M | -$124.4M |
| Capital Expenditures (CapEx) | $285.7K | $487.8K | — |
| Free Cash Flow (FCF) | -$88.9M | -$104.6M | -$124.4M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $44.3M | $65.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $24.1M | $68.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INO.